NGM Bio to Host Conference Call to Discuss Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH

Rhea-AI Summary

NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) will host a conference call on May 24, 2021, at 8:30 a.m. ET to discuss topline results from the 24-week Phase 2b ALPINE 2/3 study. This study evaluates the efficacy of aldafermin in patients with non-alcoholic steatohepatitis (NASH) and liver fibrosis. Participants will compare different doses (0.3 mg, 1 mg, and 3 mg) against a placebo. The call is open to both domestic and international callers, with archived webcasts available for 30 days.

Positive

• The upcoming conference call will provide critical topline results from the Phase 2b ALPINE 2/3 study, which could indicate the efficacy of aldafermin in treating NASH.

Negative

• None.

SOUTH SAN FRANCISCO, Calif., May 23, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) will host a conference call and live webcast on Monday, May 24, 2021 at 8:30 a.m. ET (5:30 a.m. PT) to discuss topline results from the 24-week Phase 2b ALPINE 2/3 study evaluating 0.3 mg, 1 mg and 3 mg doses of aldafermin versus placebo in patients with non-alcoholic steatohepatitis, or NASH, with stage 2 or 3 liver fibrosis. Conference call and webcast details are as follows:

Live Conference Call
Domestic Callers: (844) 873-0551
International Callers: (602) 563-8472
Passcode: 9393531

Live and Archived Webcast                                   
For the live or archived webcast, please visit the “Investors & Media” section of NGM’s website at https://ir.ngmbio.com/. The webcast will be archived for 30 days.

Archived Conference Call  
Domestic Callers: (855) 859-2056
International Callers: (404) 537-3406
Passcode: 9393531

The archived conference call will be available for 30 days.

About NGM Biopharmaceuticals, Inc.

NGM is a biopharmaceutical company focused on discovering and developing novel therapeutics based on scientific understanding of key biological pathways underlying liver and metabolic diseases, retinal diseases and cancer. We leverage our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines to patients. At NGM, we aspire to operate one of the most productive research and development engines in the biopharmaceutical industry. Visit us at www.ngmbio.com for more information.

Investor Contact: Alex Schwartz ir@ngmbio.com

Media Contact: Liz Melone media@ngmbio.com

FAQ

What are the topline results from NGM's Phase 2b ALPINE 2/3 study?

NGM will announce topline results during the conference call on May 24, 2021.

What is the purpose of the ALPINE 2/3 study conducted by NGM?

The ALPINE 2/3 study evaluates the effectiveness of aldafermin in patients with non-alcoholic steatohepatitis and liver fibrosis.

When will NGM Biopharmaceuticals hold its conference call regarding the ALPINE 2/3 study?

The conference call is scheduled for May 24, 2021, at 8:30 a.m. ET.

How can I access the webcast of NGM's conference call?

The webcast can be accessed through the Investors & Media section of NGM's website and will be archived for 30 days.

What doses of aldafermin are being evaluated in the ALPINE 2/3 study?

The study evaluates doses of 0.3 mg, 1 mg, and 3 mg of aldafermin compared to placebo.